Lndip T 10mg/40mg Tablet is a combination antihypertensive medication containing Cilnidipine 10mg and Telmisartan 40mg. Cilnidipine is a calcium channel blocker that inhibits L-type and N-type calcium channels, leading to vasodilation and reduced peripheral vascular resistance. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, resulting in vasodilation and decreased aldosterone secretion. The synergistic action of these two agents effectively lowers blood pressure by reducing systemic vascular resistance and preventing sodium and water retention. Lndip T is indicated for the management of essential hypertension, particularly in patients who require dual mechanism therapy for better blood pressure control. The combination improves patient compliance by reducing pill burden and offers a favorable safety profile with minimal adverse effects. It is contraindicated in patients with hypersensitivity to either component, severe hepatic impairment, or pregnancy. Common side effects may include dizziness, headache, and mild peripheral edema. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. Lndip T 10mg/40mg Tablet should be used under medical supervision to optimize therapeutic outcomes and minimize potential risks.